Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.

@article{Brener2013EverolimuselutingSI,
  title={Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial.},
  author={Sorin Jakob Brener and Dean J Kereiakes and Charles A. Simonton and Ali Rizvi and William Newman and Kourosh Mastali and John Chaw Chian Wang and Ronald P Caputo and R. Stephen Smith and Shih-Wa Ying and Donald E. Cutlip and Gregg Whitney Stone},
  journal={American heart journal},
  year={2013},
  volume={166 6},
  pages={1035-42}
}
OBJECTIVES We compared the outcomes of patients treated with everolimus-eluting stents (EES) versus paclitaxel-eluting stents (PES) at 3 years from the large-scale randomized SPIRIT IV trial. BACKGROUND SPIRIT IV is the largest randomized trial comparing the outcomes of EES and PES. The present report represents the final long-term follow-up analysis from… CONTINUE READING